Table 1.

Baseline Characteristics of the Participants.

Characteristic	Vaccine Group (N = 275)*	Placebo Group (N = 273)*	All Participants (N = 548)
Age — yr
Median	30.0	29.0	29.0
Range	18–45	18–45	18–45
Sex — %
Female	22	23	22
Male	78	77	78
Body-mass index†
Median	24.4	24.3	24.3
Range	17.2–55.5	16.8–53.4	16.8–55.5
Hispanic ethnic group — %‡	15	14	14
Race or ethnic group — %‡
American Indian or Alaska Native	3	<1	2
Asian, Native Hawaiian, or Pacific Islander	1	1	1
Black or African American	23	19	21
White	58	64	61
Multiracial	12	11	11
Not reported	3	4	4
IFNL3 CC genotype — %§	41	41	41

^*One participant who had been randomly assigned to the placebo group was erroneously given vaccine for both doses and is classified within the vaccine group in all summaries and analyses.

^†The body-mass index is the weight in kilograms divided by the square of the height in meters.

^‡Race and ethnic group were reported by the participants.

^§The IFNL3 CC genotype, which has been shown to enhance resolution of hepatitis C virus (HCV) infection,¹² was determined from the rs12979860 single-nucleotide polymorphism.